

Corporate News

September 05, 2017

MagForce AG to participate in seven upcoming international conferences in H2/2017

Berlin, Germany and Nevada, USA, September 05, 2017 - MagForce AG (Frankfurt, Scale, Xetra: MF6, ISIN: DE000A0HGQF5), a leading medical device company in the field of nanomedicine focused on oncology, today announced its participation in seven upcoming scientific and investor conferences in the second half of 2017:

- **Goldman Sachs Fourteenth Annual European Medtech and Healthcare Services Conference 2017**
Date: September 6-7, 2017
Location: London, UK
Presentation: Ben J. Lipps, CEO of MagForce AG, Thursday, September 7, 2017; 16:00 BST
- **Berenberg & Goldman Sachs Sixth German Corporate Conference 2017**
Date: September 18-20, 2017
Location: Munich, Germany
Presentation: Ben J. Lipps, CEO of MagForce AG, Tuesday, September 19, 2017; 11:00 CET
- **17th European Congress of Neurosurgery (EANS 2017)**
Date: October 1-5, 2017
Location: Venice, Italy
Booth: L, level: first floor
- **International Brain Tumour Alliance (IBTA) Patient's Advocate Conference**
Date: October 19-22, 2017
Location: London, UK
- **MEDICA 2017**
Date: November 13-16, 2017
Location: Düsseldorf, Germany
Community booth: Berlin Partner für Wirtschaft und Technologie GmbH No. 15F42, hall 15

Corporate News

MagForce AG • Max-Planck-Straße 3 • 12489 Berlin • Germany • www.magforce.com

For further information:
Barbara von Frankenberg
VP Communications
& Investor Relations

bfrankenberg@magforce.com
T +49-30-308380-77
F +49-30-308380-99
M +49 173-2792768

- **22nd Annual Scientific Meeting and Education Day of the Society for Neuro-Oncology (SNO)**

Date: November 16-19, 2017

Location: San Francisco, California, USA

Booth: Golden Gate foyer , level: B1

Presentation: EXPERIMENTAL THERAPEUTICS AND TUMOR MODELS,
"Combined intracavitary thermotherapy with iron-oxide nanoparticles and radiotherapy as a promising treatment modality in recurrent GBM" (SURG-32)

Presenter: Team of Prof. Dr. med. Walter Stummer, Director of the Clinic for Neurosurgery, University Hospital Münster

Speaker: PD Dr. Dr. med. Oliver Grauer, Head of Neuro-Oncology Team, University Hospital Münster

Date of presentation: Session 2C, Friday, November 17, 2017, 13:45 PDT

- **German Equity Forum 2017**

Date: November 27-29, 2017

Location: Frankfurt, Germany

Presentation: Ben J. Lipps, CEO of MagForce AG, Tuesday, September 28, 2017; 16:30 CET

Room: Oslo

About MagForce AG and MagForce USA, Inc.

MagForce AG, listed in the Scale segment of the Frankfurt Stock Exchange (MF6, ISIN: DE000A0HGQF5), together with its subsidiary MagForce USA, Inc. is a leading medical device company in the field of nanomedicine focused on oncology. The Group's proprietary NanoTherm® therapy enables the targeted treatment of solid tumors through the intratumoral generation of heat via activation of superparamagnetic nanoparticles.

NanoTherm®, NanoPlan®, and NanoActivator® are components of the therapy and have received EU-wide regulatory approval as medical devices for the treatment of brain tumors. MagForce, NanoTherm, NanoPlan, and NanoActivator are trademarks of MagForce AG in selected countries.

For more information, please visit: www.magforce.com

Get to know our Technology: [video \(You Tube\)](#)

Stay informed and subscribe to our [mailing list](#)

Corporate News

MagForce AG • Max-Planck-Straße 3 • 12489 Berlin • Germany • www.magforce.com

For further information:
Barbara von Frankenberg
VP Communications
& Investor Relations

bfrankenberg@magforce.com
T +49-30-308380-77
F +49-30-308380-99
M +49 173-2792768

Disclaimer

This release may contain forward-looking statements and information which may be identified by formulations using terms such as "expects", "aims", "anticipates", "intends", "plans", "believes", "seeks", "estimates" or "will". Such forward-looking statements are based on our current expectations and certain assumptions, which may be subject to a variety of risks and uncertainties. The results actually achieved by MagForce AG may substantially differ from these forward-looking statements. MagForce AG assumes no obligation to update these forward-looking statements or to correct them in case of developments, which differ from those, anticipated.

Corporate NewsMagForce AG • Max-Planck-Straße 3 • 12489 Berlin • Germany • www.magforce.com

For further information:
Barbara von Frankenberg
VP Communications
& Investor Relations

bfrankenberg@magforce.com
T +49-30-308380-77
F +49-30-308380-99
M +49 173-2792768